This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Trechot P. Comment on “Levothyrox® New and Old Formulations: Are they Switchable for Millions of Patients?”. Clin Pharmacokinet. 2019. https://doi.org/10.1007/s40262-019-00784-y.
Concordet D, Gandia P, Montastruc J-L, Bousquet-Mélou A, Lees P, Ferran A, et al. Levothyrox® new and old formulations: are they switchable for millions of patients? Clin Pharmacokinet. 2019. https://doi.org/10.1007/s40262-019-00747-3(epub 4 Apr 2019).
Aronson JK, La Caze A, Kelly MP, Parkkinen V-P, Williamson J. The use of mechanistic evidence in drug approval. J Eval Clin Pract. 2018;24:1166–76.
Lindenberg M, Kopp S, Dressman JB. Classification of orally administered drugs on the World Health Organization Model list of essential medicines according to the biopharmaceutics classification system. Eur J Pharm Biopharm. 2004;58:265–78.
Chen M-L, Sadrieh N, Yu L. Impact of osmotically active excipients on bioavailability and bioequivalence of BCS class III drugs. AAPS J. 2013;15:1043–50.
Shah HS, Chaturvedi K, Hamad M, Bates S, Hussain A, Morris K. New insights on solid-state changes in the levothyroxine sodium pentahydrate during dehydration and its relationship to chemical instability. AAPS PharmSciTech. 2019;20:39.
No sources of funding were used in the preparation of this reply.
Conflict of interest
Didier Concordet, Peggy Gandia, Jean-Louis Montastruc, Alain Bousquet-Mélou, Peter Lees, Aude A. Ferran, and Pierre-Louis Toutain declare no relevant potential conflicts of interest.
About this article
Cite this article
Concordet, D., Gandia, P., Montastruc, J. et al. Author’s Reply to Trechot: “Comment on Levothyrox® New and Old Formulations: Are they Switchable for Millions of Patients?”. Clin Pharmacokinet 58, 979–980 (2019). https://doi.org/10.1007/s40262-019-00787-9